一、对外投资概述 证券代码：603387 证券简称：基蛋生物 公告编号：2023-023 基蛋生物科技股份有限公司 关于投资建设研发及办公综合大楼的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资项目名称：研发及办公综合大楼 投资金额：预计总投资 4 亿元人民币，包含土地价款、建筑主体工程及 配套设施工程费用。项目最终投资总额以实际投资金额为准。 相关风险提示：在项目建设过程中，可能存在相关政策、宏观经济等方 面的不确定性风险，有可能会影响项目的正常实施。公司将根据实际情况，依法 合规推行项目进展，规避项目风险。 为满足公司未来发展规划对经营场所的需求，优化资源配置，为公司的可持 续长远发展提供有力的硬件保障，公司投资建设研发及办公综合大楼。该项目占 地面积约 36,976 平方米，总建筑面积约 95,912 平方米，其中地上建筑面积约 73,794 平方米，地下建筑面积约 22,118 平方米，主要建筑内容为集研发、办公 等功能于一体的综合大楼及其他相关配套设施。公司已取得项目所需建设用地以 及《投 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-027 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 09 月 12 日上午 10:00-11:00 基蛋生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于2023年09月05日(星期二)至09月11日(星期一)16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱IR@getein.cn进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 基蛋生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上 半年度经营成果、财务状况，公司计划于 2 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-026 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第三届监事会第十一次会 议的通知已于2023年8月18日以电子邮件的方式发出，通知了全体监事和其他列 席人员。公司本次监事会会议于2023年8月28日以通讯表决方式召开。会议应到 监事人3人，实到监事3人；公司董事会秘书和财务负责人列席了本次监事会会议。 会议由监事会主席李靖召集和主持。本次会议召集、召开符合《中华人民共 和国公司法》及有关法律、法规和《公司章程》的规定。 二、监事会会议审议情况 （一）审议并通过《关于<公司2023年半年度报告>及其摘要的议案》 基蛋生物科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司全体监事出席本次会议 是否有监事投反对或弃权票：否 本次监事会议案全部获得通过 监事会核查本项议案后认为：《公司2023年半年度报告》的编制和审议程序 符合法律、法规、《公司章程》和公司内部管理制度的 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-022 基蛋生物科技股份有限公司 关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：向全体股东每10股派发人民币1元（含税）。 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确,在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 基蛋生物科技股份有限公司（合并报表） 2023年1-6月实现净利润 171,580,000.10元，其中归属上市公司股东的净利润168,720,454.45元。2023年 半年度公司（合并报表）可供分配利润1,471,522,388.59元，母公司可供分配利 润1,249,703,008.38元（数据未经审计）。 基于对公司未来发展的良好预期，综合考虑公司经营现状、资产规模及盈余 情况，在保证公司正常经营和长远发展的前提下，为回报全 ...

2023 年第一季度报告 证券代码：603387 证券简称：基蛋生物 基蛋生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 项目 本报告期 本报告期比上年同期增减 变动幅度(%) 营业收入 384,316,306.14 -32.66 归属于上市公司股东的净利润 121,526,036.35 -44.44 归属于上市公司股东的扣除非经常 性损益的净利润 100,536,845.57 -54.32 经营活动产生的现金流量净额 13,484,563.45 -79.84 基本每股收益（元/股） 0.24 -44 ...

Financial Performance - In 2022, the company achieved a net profit of RMB 503,944,698.54, with a net profit attributable to shareholders of RMB 498,909,980.40[6]. - The company proposed a cash dividend of RMB 3 per 10 shares, amounting to a total cash dividend of RMB 152,146,055.10, which represents 30.50% of the net profit attributable to shareholders[7]. - The total distributable profit for 2022 was RMB 1,454,947,989.25, after accounting for the profit distribution and retained earnings[6]. - The parent company reported a net profit of RMB 433,531,627.04 for 2022, with a total distributable profit of RMB 1,228,815,194.65[6]. - The company's operating revenue for 2022 reached ¥1,821,860,703.15, representing a year-on-year increase of 29.97%[25]. - The net profit attributable to shareholders for 2022 was ¥498,909,980.40, up 25.04% compared to the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.59% to ¥461,538,014.58[25]. - Basic earnings per share for 2022 were ¥0.98, an increase of 24.05% from ¥0.79 in 2021[26]. - The weighted average return on equity for 2022 was 21.76%, up from 20.43% in 2021[26]. - Total assets at the end of 2022 amounted to ¥3,677,437,948.24, reflecting a year-on-year growth of 17.19%[25]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company received a standard unqualified audit report from Zhongtian Yun Accounting Firm[5]. Research and Development - The company achieved a research and development investment of 26,205.90 million yuan, a year-on-year increase of 40.19%, accounting for 14.38% of operating revenue[49]. - The number of R&D personnel increased to 632, up by 184 from the beginning of 2022[49]. - The company has 500 valid patents as of December 31, 2022, with 310 authorized patents, including 30 invention patents[49]. - The company has developed eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular diagnostics, enhancing its product system from single POCT products to a diverse range[70]. - The company is committed to continuous innovation in product development, focusing on unmet clinical needs[50]. Product Development and Market Expansion - The company launched several new products, including the MAGICL6200 fully automated chemiluminescence analyzer (400T/H) and the CM1000 fully automated biochemical analyzer (1000T/H)[50]. - The company launched the Metis600 emergency blood cell line, which integrates multiple testing capabilities for clinical needs, including blood routine, inflammation, cardiovascular, and glycation tests[40]. - The company is focusing on expanding its market share in grade hospitals by increasing penetration in previously untapped departments[38]. - The company has expanded its chemiluminescence product line to 78 items, including 11 cardiovascular projects, maintaining a leading position in the market[44]. - The company aims to further develop its product offerings in areas such as coagulation series and liver cancer screening, enhancing its competitive edge in the chemiluminescence market[46]. Marketing and Sales Strategy - The company implemented a dual-driven marketing reform strategy focusing on "core" and "collaboration" to enhance growth[52]. - The company has established a comprehensive after-sales service system with over 200 frontline engineers and 30 technical engineers nationwide[59]. - The company is focusing on proactive maintenance and upgrades for large instruments to improve customer satisfaction[59]. - The company aims to leverage new policies to enhance the construction of county-level medical institutions, benefiting the IVD sector[66]. - The company is focusing on expanding its direct sales team to enhance customer loyalty and market barriers[81]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[153]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to oversee financial conditions and major matters[154]. - The company has established a robust information disclosure system, ensuring timely and accurate communication of significant information to shareholders[155]. - The company maintains independent operations with complete assets, personnel, and financial systems, ensuring no conflicts of interest with controlling shareholders[156]. - The company has conducted 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders and no rejected resolutions[159]. Employee and Management Practices - The company has established a comprehensive welfare system for employees, including various benefits to enhance employee satisfaction and belonging[184]. - The company conducted training programs focusing on R&D processes, safety production, and management talent development during the reporting period[185]. - The company’s remuneration policy aims to align employee development with corporate interests, ensuring fair and competitive compensation[184]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0898 million yuan[170]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[167]. - The company plans to invest 200 million RMB in marketing to support the launch of new products and enhance brand visibility[167]. - The company aims to establish wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa to deepen local market penetration[143]. - The company plans to increase R&D investment and strengthen technological innovation to enhance core competitiveness and improve operational performance[151].

证券代码：603387 证券简称：基蛋生物 公告编号：2023-012 基蛋生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 18 日上午 09:00-10:00 会议召开时间：2023年05月18日(星期四)上午09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于2023年05月11日(星期四)至05月17日(星期三)16:00前登录 上证路演中心网站首页点击"提问预 ...

2022 年第三季度报告 证券代码：603387 证券简称：基蛋生物 基蛋生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 13 项目 本报告期 本报告期 比上年同 期增减变 动幅度(%) 年初至报告期末 年初至报 告期末比 上年同期 增减变动 幅度(%) 营业收入 403,956,352.10 25.50 1,377,167,848.88 49.34 归属于上市公司股东的净 利润 145,399,343.30 76.76 475,201,070.04 87.74 归属于上市公司股东的扣 除非经常性损益的净利润 13 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of the year reached ¥973,211,496.78, representing a 62.12% increase compared to ¥600,288,159.94 in the same period last year[20]. - Net profit attributable to shareholders increased by 93.03% to ¥329,801,726.74 from ¥170,856,236.75 year-on-year[22]. - The net profit after deducting non-recurring gains and losses rose by 107.68% to ¥324,746,556.32 compared to ¥156,371,441.63 in the previous year[22]. - The company's cash flow from operating activities increased by 13.80% to ¥139,398,475.54, up from ¥122,489,994.89 in the same period last year[22]. - Basic earnings per share rose by 91.17% to ¥0.65 from ¥0.34 year-on-year[21]. - The company's total assets grew by 10.35% to ¥3,462,750,351.49 from ¥3,137,931,357.50 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 9.76% to ¥2,311,900,340.42 from ¥2,106,400,196.02 at the end of the previous year[20]. - The company achieved operating revenue of 973.21 million yuan, a year-on-year increase of 62.12%[51]. - The revenue from in vitro diagnostic business was 831 million yuan, reflecting a significant growth of 90.04%[51]. - The company reported a total operating profit of ¥341,905,801.15 for the first half of 2022, up from ¥150,030,047.62 in the same period of 2021, representing a growth of about 128.5%[140]. Market Expansion and Product Development - User data indicated an increase in active users by 25%, reaching a total of 5 million users by June 30, 2022[12]. - The company plans to launch three new products in the next quarter, focusing on point-of-care testing (POCT) technology[12]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2022[12]. - The company is actively expanding its product lines and pursuing overseas strategies, contributing to revenue growth[22]. - The company is actively promoting new projects in various diagnostic areas, including myocardial markers, inflammation, and tumor markers[36]. - The company is focusing on market expansion, targeting a 30% increase in market share in key regions over the next two years[176]. - A strategic acquisition was announced, which is expected to contribute an additional 500 million in revenue annually starting next fiscal year[178]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[168]. Research and Development - The company is investing RMB 100 million in R&D for new diagnostic technologies, with a focus on enhancing product accuracy and speed[12]. - R&D investment for the first half of 2022 was 116.16 million yuan, representing a year-on-year increase of 45.73% and accounting for 11.93% of operating revenue[47]. - The company has established seven major technology platforms, enhancing its core competitiveness in the in vitro diagnostic industry[46]. - The company is committed to enhancing its R&D capabilities, focusing on small and high-speed chemiluminescence instruments and comprehensive reagent support[44]. - The company is actively researching and developing products for emerging health threats, such as monkeypox, and has completed EU registration for these products[37]. - The company has obtained 53 new product registration certificates in the first half of 2022, bringing the total to 1,209, including 359 domestic and 850 foreign certificates[56]. Operational Efficiency - The company has established a dynamic capacity adjustment mechanism to respond quickly to market demand, ensuring timely order fulfillment and maintaining reasonable inventory levels[38]. - The company emphasizes cost control through optimized supply chain management and has achieved favorable procurement costs, enhancing overall product competitiveness[37]. - The company has a robust production model that combines sales forecasting with a make-to-order approach, ensuring efficient production and inventory management[38]. - The company has implemented a flexible sales model that combines distribution and direct sales, enhancing its ability to innovate and respond to clinical demands[40]. Financial Management and Shareholder Commitments - The company reported a net cash outflow from investing activities of ¥45,355,737.88, a significant decrease of 141.61% from a net inflow of ¥109,010,969.85 in the previous period[60]. - The company has established commitments to avoid any potential competition from its actual controller and related parties[103]. - The controlling shareholder has pledged not to transfer shares for 36 months post-IPO, with specific conditions for any future share reductions[96]. - The company will notify the public three trading days in advance of any share reduction plans, including quantity and price range[100]. - The commitments made by shareholders and senior management are subject to public supervision and regulatory oversight[102]. Environmental and Social Responsibility - The company reported that it does not belong to the key pollutant discharge units and has implemented appropriate measures for environmental protection[82]. - The wastewater generated by the company meets the Class 3 standard of the Comprehensive Wastewater Discharge Standard (GB8979-1996) after pretreatment[83]. - The company has installed an online monitoring system for wastewater discharge, ensuring compliance with environmental standards[83]. - The company donated 644,000 RMB to the University of Science and Technology of China for COVID-19 crisis management training for medical personnel and related patients[89].

编号：2022-001 证券代码：603387 证券简称：基蛋生物 基蛋生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------------|---------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | | | □媒体采访 ■业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 □一对一沟通 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及人员 | 光大证券 | | | 姓名 | 浙商证券 | | | | 中信证券 | | | | 申万宏源证券 | | | | 华安证券等 | | | 时间 | 2022 年 4 月 28 日 | 15：00-16：00；16:30 — 17:30 | | 地点 | 线上交流 | | | 上市公司接待人员 | | 董事长苏恩本先生、财务总监倪文先生 ...